The updated version may include a body weight decrease by 15% for obese patients, underlining the necessity for treatment with either a GLP-1RA or tirzepatide to reach this therapeutic goal
Anyone starting or continuing a compounded GLP-1 program right now should understand the FDA's April 2026 proposal, ask their telehealth platform about pharmacy structure, and have a conversation with their clinician about contingency planning for their care if compounding availability changes
It is best not to use a medication after its expiration date or if it has not been properly stored
Gradually reintroduce fiber-rich foods once symptoms improve, starting with small amounts of soluble fiber like oatmeal or bananas
Starting at a low dose and increasing slowly helps
For someone who is already at a healthy weight and wants to reduce a few pounds of stubborn subcutaneous fat without any systemic effects, tirzepatide is probably more tool than the job requires, and AOD 9604 gentle approach may be all that is needed